九典制药(300705)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300705 九典制药

已收盘 09-23 15:00:00

{"stockData":{"symbol":"300705","market":"SZ","secType":"STK","nameCN":"九典制药","latestPrice":17.12,"timestamp":1758611037000,"preClose":17.57,"halted":0,"volume":13704857,"delay":0,"changeRate":-0.0256,"floatShares":370000000,"shares":500000000,"eps":1.0389,"marketStatus":"已收盘","change":-0.45,"latestTime":"09-23 15:00:00","open":17.49,"high":17.53,"low":16.84,"amount":234000000,"amplitude":0.0393,"askPrice":17.12,"askSize":458,"bidPrice":17.11,"bidSize":491,"shortable":0,"etf":0,"ttmEps":1.0389,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1758677400000},"marketStatusCode":5,"adr":0,"adjPreClose":17.57,"symbolType":"stock","openAndCloseTimeList":[[1758591000000,1758598200000],[1758603600000,1758610800000]],"highLimit":19.33,"lowLimit":15.81,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":500212355,"isCdr":false,"pbRate":3.46,"roa":"--","peRate":16.478968,"roe":"11.12%","epsLYR":1.05,"committee":0.191201,"marketValue":8564000000,"turnoverRate":0.0371,"status":1,"floatMarketCap":6331000000},"requestUrl":"/m/hq/s/300705","defaultTab":"news","newsList":[{"id":"2568237019","title":"天风证券：给予九典制药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2568237019","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568237019?lang=zh_cn&edition=full","pubTime":"2025-09-19 15:00","pubTimestamp":1758265259,"startTime":"0","endTime":"0","summary":"天风证券股份有限公司杨松近期对九典制药进行研究并发布了研究报告《公司经营稳健，拓展外用制剂管线+加速创新药转型》，给予九典制药买入评级。随着未来新品逐渐上市销售，叠加老龄化日益严重、经皮给药市场需求增加的外部环境驱动，公司在外用制剂板块有望持久续航。2025-2027年对应当前市值15/14/12XPE，维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091900017290.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601162","300705"],"gpt_icon":0},{"id":"2567100924","title":"九典制药：回购股份主要用于员工股权激励","url":"https://stock-news.laohu8.com/highlight/detail?id=2567100924","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567100924?lang=zh_cn&edition=full","pubTime":"2025-09-16 20:52","pubTimestamp":1758027128,"startTime":"0","endTime":"0","summary":"证券之星消息，九典制药09月16日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，此前公司公告累计回购1.24%股份，传递出对自身发展的信心。想请教下，本次回购股份后续是否有明确的用途规划？公司本次回购的股份后续将主要用于员工股权激励，旨在建立和完善长效激励机制，充分调动核心团队积极性，有效将股东、公司和员工利益相结合，促进公司长期稳健发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091600035855.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2567174588","title":"九典制药：椒七止痛凝胶贴膏有望2026年底获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2567174588","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567174588?lang=zh_cn&edition=full","pubTime":"2025-09-16 15:04","pubTimestamp":1758006274,"startTime":"0","endTime":"0","summary":"证券之星消息，九典制药09月16日在投资者关系平台上答复投资者关心的问题。这些项目是否与当前市场需求热点契合，未来有望为公司打开怎样的增长空间？若审批进展顺利，公司自主研发的中药Ⅰ类新药椒七止痛凝胶贴膏有望于2026年底获批上市。该产品上市后将依托公司成熟的销售网络优先布局院内市场，同时积极拓展院外市场。作为国内首款中药凝胶贴膏，该产品上市后将进一步丰富公司产品线，提升公司在中药外用制剂领域的竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091600019073.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2567451169","title":"九典制药：易格私募基金、甬兴证券等多家机构于9月12日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2567451169","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567451169?lang=zh_cn&edition=full","pubTime":"2025-09-15 09:20","pubTimestamp":1757899218,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年9月12日九典制药发布公告称易格私募基金、甬兴证券于2025年9月12日调研我司。因主要规则正式文件尚未发布，对价格降幅暂无法做具体估算。经测算，2025 年全年研发费用预计在 2.5 亿至 3亿元之间。根据目前的研发进展，JIJ02 凝胶预计将于明年上半年完成Ⅰ期临床试验，并启动Ⅱ期临床。公司对消炎解痛巴布膏的市场前景持乐观态度。该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091500002708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705","161027"],"gpt_icon":0},{"id":"2564114846","title":"九典制药(300705.SZ)：累计回购1.24%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2564114846","media":"格隆汇","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564114846?lang=zh_cn&edition=full","pubTime":"2025-09-01 22:19","pubTimestamp":1756736352,"startTime":"0","endTime":"0","summary":"9月1日丨九典制药(300705.SZ)公布，截至2025年8月31日，公司通过股份回购专用证券账户以集中竞价交易方式累计回购股份6,180,800股，占公司目前总股本的1.24%，最高成交价为18.44元/股，最低成交价为14.51元/股，成交总金额为1.00亿元(不含交易费用)。\n\n\r\n            责任编辑：小讯","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/09/01221952853745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2564165248","title":"九典制药最新公告：取得椒七止痛凝胶贴膏Ⅲ期临床试验总结报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2564165248","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564165248?lang=zh_cn&edition=full","pubTime":"2025-09-01 18:10","pubTimestamp":1756721402,"startTime":"0","endTime":"0","summary":"九典制药(300705.SZ)公告称，公司近日取得椒七止痛凝胶贴膏Ⅲ期临床试验总结报告。该药物属于中药1.1类，功能主治为温经散寒、活血止痛。临床试验结论显示，该药物能有效改善膝骨关节炎引起的疼痛，且起效较快，可改善患者临床症状及活动能力，用药安全性较好。然而，公司需向国家药品监督管理局提出注册申请，经审批通过后方可上市销售。药物研发存在不确定性风险，公司将及时履行信息披露义务。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090100025651.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2562781205","title":"九典制药：氟比洛芬凝胶贴膏预计年底获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2562781205","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562781205?lang=zh_cn&edition=full","pubTime":"2025-08-26 11:34","pubTimestamp":1756179252,"startTime":"0","endTime":"0","summary":"证券之星消息，九典制药(300705)08月26日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好，非常关注公司氟比洛芬凝胶贴膏的审批情况，请问目前该药品在审批流程中处于什么状态 ，距离获批还有哪些关键节点？九典制药回复：尊敬的投资者：您好！目前，该药品正处于补充资料审评阶段。结合当前审批进度，我们预计该药品有望在今年年底获批，但药品审评审批属于行政审批事项，存在一定的不确定性，敬请注意投资风险。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082600019751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2562264433","title":"股市必读：九典制药中报 - 第二季度单季净利润同比增长4.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562264433","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562264433?lang=zh_cn&edition=full","pubTime":"2025-08-25 04:18","pubTimestamp":1756066690,"startTime":"0","endTime":"0","summary":"业绩披露要点：九典制药2025年中报显示，公司主营收入15.12亿元，同比增长10.67%，归母净利润2.91亿元，同比增长2.57%，毛利率为74.58%。股本股东变化截至2025年6月30日，九典制药股东户数为3.88万户，较3月31日减少5108户，减幅为11.65%。其中2025年第二季度，公司单季度主营收入8.16亿元，同比上升5.24%；单季度归母净利润1.66亿元，同比上升4.54%；单季度扣非净利润1.59亿元，同比上升6.62%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082500000968.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705"],"gpt_icon":0},{"id":"2561532882","title":"九典制药（300705）2025年中报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2561532882","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561532882?lang=zh_cn&edition=full","pubTime":"2025-08-24 06:18","pubTimestamp":1755987491,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期九典制药发布2025年中报。根据财报显示，九典制药营收净利润同比双双增长。截至本报告期末，公司营业总收入15.12亿元，同比上升10.67%，归母净利润2.91亿元，同比上升2.57%。按单季度数据看，第二季度营业总收入8.16亿元，同比上升5.24%，第二季度归母净利润1.66亿元，同比上升4.54%。去年的净利率为17.48%，算上全部成本后，公司产品或服务的附加值高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082400001762.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705"],"gpt_icon":0},{"id":"2561420104","title":"九典制药(300705)6月30日股东户数3.88万户，较上期减少11.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2561420104","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561420104?lang=zh_cn&edition=full","pubTime":"2025-08-22 17:44","pubTimestamp":1755855847,"startTime":"0","endTime":"0","summary":"证券之星消息，近日九典制药披露，截至2025年6月30日公司股东户数为3.88万户，较3月31日减少5108.0户，减幅为11.65%。在化学制药行业个股中，九典制药股东户数高于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.29万户。从股价来看，2025年3月31日至2025年6月30日，九典制药区间跌幅为10.38%，在此期间股东户数减少5108.0户，减幅为11.65%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082200033116.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2561241924","title":"九典制药(300705.SZ)发布上半年业绩，归母净利润2.91亿元，增长2.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2561241924","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561241924?lang=zh_cn&edition=full","pubTime":"2025-08-22 16:33","pubTimestamp":1755851596,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九典制药(300705.SZ)发布2025年半年度报告，该公司营业收入为15.12亿元，同比增长10.67%。归属于上市公司股东的净利润为2.91亿元，同比增长2.57%。归属于上市公司股东的扣除非经常性损益的净利润为2.83亿元，同比增长10.74%。基本每股收益为0.59元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1333461.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300705"],"gpt_icon":0},{"id":"2561344451","title":"九典制药：公司目前的研发进展符合预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2561344451","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561344451?lang=zh_cn&edition=full","pubTime":"2025-08-22 11:33","pubTimestamp":1755833588,"startTime":"0","endTime":"0","summary":"证券之星消息，九典制药08月21日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好，公司预计2025年获批的吲哚美辛凝胶贴膏、氟比洛芬凝胶贴膏等产品，目前研发进展是否符合预期？公司目前的研发进展符合预期，公司将持续打造“久悦”贴膏品牌，通过先发优势、渠道优势及成本优势等，致力于在经皮给药领域深化影响力，进一步稳固行业领先地位。感谢您对公司的关注！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082200016811.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2561468306","title":"九典制药：受让取得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2561468306","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561468306?lang=zh_cn&edition=full","pubTime":"2025-08-21 17:13","pubTimestamp":1755767581,"startTime":"0","endTime":"0","summary":"九典制药公告，公司以9000万元受让成都佩德生物医药有限公司拥有的JIJ02凝胶（原申报名称“PD-DP-008凝胶”）的全部已开发成果及相应知识产权，并签署了《技术转让合同书》。药品名称为JIJ02凝胶，注册分类为化学药品1类，拟定适应症为寻常痤疮。公司受让取得该药物临床试验批准通知书不会对公司的财务状况和经营业绩构成重大影响。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/08/21171352589929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2560191268","title":"九典制药：公司目前未收到实际控制人控股股东及董监高的减持计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2560191268","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560191268?lang=zh_cn&edition=full","pubTime":"2025-08-19 20:52","pubTimestamp":1755607931,"startTime":"0","endTime":"0","summary":"证券之星消息，九典制药(300705)08月19日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好！请问贵公司最近有没有大股东减持计划，另外，请问最新股东户数是多少？谢谢！九典制药回复：尊敬的投资者：您好！公司目前未收到实际控制人、控股股东及董监高的减持计划。如有相关事项，公司将根据相关规定履行信息披露义务。公司股东人数按规定在定期报告中进行披露，请参见公司定期报告。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081900038154.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2559273993","title":"九典制药：国内客户主要为国内大型的商业配送公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2559273993","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559273993?lang=zh_cn&edition=full","pubTime":"2025-08-15 09:09","pubTimestamp":1755220144,"startTime":"0","endTime":"0","summary":"证券之星消息，九典制药(300705)08月15日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司与国内外哪些公司有合作？九典制药回复：尊敬的投资者：您好！公司客户以国内为主，国外客户业务体量都比较小。国内客户主要为国内大型的商业配送公司。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081500008528.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2557737437","title":"九典制药：预计2025年度营收同比增长10%—20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557737437","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557737437?lang=zh_cn&edition=full","pubTime":"2025-08-06 20:15","pubTimestamp":1754482551,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2555953072","title":"昨日化学制药行业主力净流出超25亿元，金石亚药、九典制药、科伦药业等靠前","url":"https://stock-news.laohu8.com/highlight/detail?id=2555953072","media":"制药网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555953072?lang=zh_cn&edition=full","pubTime":"2025-07-31 11:16","pubTimestamp":1753931766,"startTime":"0","endTime":"0","summary":"2025 年 7 月 30 日，化学制药行业呈现出引人瞩目的资金动态，主力资金流出规模高达 25.19 亿元。其中主力资金净流出靠前的包括金石亚药、九典制药、科伦药业、尔康制药、纳微科技。金石亚药业务涵盖药品和保健食品研发、生产与销售。近日金石亚药公告称，预计2025年1-6月归属于上市公司股东的净利润盈利:5,881.72万元至7,261.78万元,同比上年增长:50.04%至85.24%。近日，九典制药迎来多家机构调研。化学制药行业主力资金的大规模流出，背后原因复杂多样。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073111165994c52f17&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073111165994c52f17&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","BK0028","BK0239","LU1934453819.USD","BK0229","300434","BK0060","002422","300705","LU2148510915.USD","LU1064130708.USD","LU1064131003.USD","BK0077","LU1979443071.USD","688690"],"gpt_icon":0},{"id":"2555700240","title":"九典制药：信达证券投资者于7月28日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2555700240","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555700240?lang=zh_cn&edition=full","pubTime":"2025-07-29 09:06","pubTimestamp":1753751166,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年7月28日九典制药发布公告称信达证券于2025年7月28日调研我司。答：洛索洛芬钠凝胶贴膏在地方集采的中标价格是17-18元左右。九典制药主营业务：医药产品的研发、生产和销售。九典制药2025年一季报显示，公司主营收入6.96亿元，同比上升17.79%；归母净利润1.26亿元，同比上升0.08%；扣非净利润1.24亿元，同比上升16.54%；负债率24.06%，投资收益17.07万元，财务费用242.3万元，毛利率73.57%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072900007808.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601059","BK0239","300705","BK0276"],"gpt_icon":0},{"id":"2555700282","title":"九典制药：公司治疗关节痛的药品有洛索洛芬钠凝胶贴膏、酮洛芬凝胶贴膏、消炎解痛巴布膏、酮洛芬凝胶等产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2555700282","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555700282?lang=zh_cn&edition=full","pubTime":"2025-07-29 09:01","pubTimestamp":1753750875,"startTime":"0","endTime":"0","summary":"证券之星消息，九典制药(300705)07月28日在投资者关系平台上答复投资者关心的问题。投资者提问：基孔肯雅热的典型症状是关节痛和发热，贵公司有治疗关节痛得膏药吗？还有退热的九典制药回复：尊敬的投资者：您好！公司治疗关节痛的药品有洛索洛芬钠凝胶贴膏、酮洛芬凝胶贴膏、消炎解痛巴布膏、酮洛芬凝胶等产品，解热药品有洛索洛芬钠片和洛索洛芬钠口服溶液等产品，感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072900007676.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2554427754","title":"九典制药：公司有对乙酰氨基酚片批文但暂未生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2554427754","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554427754?lang=zh_cn&edition=full","pubTime":"2025-07-25 15:48","pubTimestamp":1753429693,"startTime":"0","endTime":"0","summary":"证券之星消息，九典制药(300705)07月25日在投资者关系平台上答复投资者关心的问题。投资者提问：基孔肯雅热，只有对乙酰氨基酚有用，贵公司生产吗？九典制药回复：尊敬的投资者：您好！公司有对乙酰氨基酚片的批文，但目前暂未生产该药品。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072500021923.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1758622616399,"stockEarnings":[{"period":"1week","weight":-0.0118},{"period":"1month","weight":-0.1059},{"period":"3month","weight":0.1321},{"period":"6month","weight":0.0234},{"period":"1year","weight":-0.0078},{"period":"ytd","weight":-0.0017}],"compareEarnings":[{"period":"1week","weight":-0.0083},{"period":"1month","weight":0.0007},{"period":"3month","weight":0.1193},{"period":"6month","weight":0.1365},{"period":"1year","weight":0.3989},{"period":"ytd","weight":0.1423}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖南九典制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"38753人(较上一季度减少11.65%)","perCapita":"9542股","listingDate":"2017-10-10","address":"湖南省长沙市浏阳市经济技术开发区健康大道1号","registeredCapital":"50021万元","survey":"　　湖南九典制药股份有限公司的主营业务是化药制剂、原料药、药用辅料、中药、大健康产品等的研发、生产、销售、CXO服务。公司的主要产品是药品制剂、原料药及药用辅料。公司先后获评安全生产标准化三级企业、安全生产示范企业等称号。","listedPrice":10.37},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.3","shortVersion":"4.35.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"九典制药(300705)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供九典制药(300705)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"九典制药,300705,九典制药股票,九典制药股票老虎,九典制药股票老虎国际,九典制药行情,九典制药股票行情,九典制药股价,九典制药股市,九典制药股票价格,九典制药股票交易,九典制药股票购买,九典制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"九典制药(300705)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供九典制药(300705)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}